A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma.

[1]  R. Peeters,et al.  Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer. , 2018, Thyroid : official journal of the American Thyroid Association.

[2]  C. Benbassat,et al.  Reassessment of Differentiated Thyroid Cancer Patients Using the Eighth TNM/AJCC Classification System: A Comparative Study. , 2017, Thyroid : official journal of the American Thyroid Association.

[3]  S. Roman,et al.  Projecting Survival in Papillary Thyroid Cancer: A Comparison of the Seventh and Eighth Editions of the American Joint Commission on Cancer/Union for International Cancer Control Staging Systems in Two Contemporary National Patient Cohorts. , 2017, Thyroid : official journal of the American Thyroid Association.

[4]  M. Ge,et al.  Number of Metastatic Lymph Nodes and Ratio of Metastatic Lymph Nodes to Total Number of Retrieved Lymph Nodes Are Risk Factors for Recurrence in Patients With Clinically Node Negative Papillary Thyroid Carcinoma , 2017, Clinical and experimental otorhinolaryngology.

[5]  Dae Cheon Jeong,et al.  Outcome prediction with the revised American joint committee on cancer staging system and American thyroid association guidelines for thyroid cancer , 2017, Endocrine.

[6]  Tae Yong Kim,et al.  Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer. , 2017, Thyroid : official journal of the American Thyroid Association.

[7]  Jee Soo Kim,et al.  Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma. , 2017, Oral oncology.

[8]  Tae Yong Kim,et al.  Optimal cut‐off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years? , 2017, Clinical endocrinology.

[9]  D. Grimm,et al.  Effects and Role of Multikinase Inhibitors in Thyroid Cancer. , 2016, Current pharmaceutical design.

[10]  Y. Chae,et al.  Predicting Extrathyroidal Extension in Patients With Papillary Thyroid Microcarcinoma According to a BRAF Mutation , 2016, Clinical and experimental otorhinolaryngology.

[11]  M. Merlano,et al.  Follow-up in Head and Neck Cancer: Do More Does It Mean Do Better? A Systematic Review and Our Proposal Based on Our Experience , 2016, Clinical and experimental otorhinolaryngology.

[12]  J. Park,et al.  Preoperative Lymph Node Staging by FDG PET/CT With Contrast Enhancement for Thyroid Cancer: A Multicenter Study and Comparison With Neck CT , 2016, Clinical and experimental otorhinolaryngology.

[13]  J. Shah,et al.  An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer. , 2016, Thyroid : official journal of the American Thyroid Association.

[14]  J. Shah,et al.  Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer , 2016, Annals of Surgical Oncology.

[15]  J. Shah,et al.  The impact of nodal status on outcome in older patients with papillary thyroid cancer. , 2014, Surgery.

[16]  A. Stojadinovic,et al.  Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome. , 2014, Thyroid : official journal of the American Thyroid Association.

[17]  A. Gill,et al.  Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma. , 2013, Surgery.

[18]  S. Mandel,et al.  The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. , 2012, Thyroid : official journal of the American Thyroid Association.

[19]  Ahmedin Jemal,et al.  Cancers with increasing incidence trends in the United States: 1999 through 2008 , 2012, CA: a cancer journal for clinicians.

[20]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[21]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[22]  T. Fahey,et al.  Extrathyroidal extension is not all equal: Implications of macroscopic versus microscopic extent in papillary thyroid carcinoma. , 2008, Surgery.

[23]  Koichi Ito,et al.  Lymph Node Metastasis From 259 Papillary Thyroid Microcarcinomas: Frequency, Pattern of Occurrence and Recurrence, and Optimal Strategy for Neck Dissection , 2003, Annals of surgery.

[24]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[25]  M. van Glabbeke,et al.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. , 1979, European journal of cancer.

[26]  Nancy D Perrier,et al.  Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2018, CA: a cancer journal for clinicians.

[27]  C. Benbassat,et al.  Reassessment of Differentiated Thyroid Cancer Patients Using the Eighth TNM/AJCC Classification System: A Comparative Study. , 2018, Thyroid : official journal of the American Thyroid Association.

[28]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[29]  A. Buck,et al.  Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. , 2013, The Journal of clinical endocrinology and metabolism.

[30]  M. Hirokawa,et al.  Clinical significance of extrathyroid extension to the parathyroid gland of papillary thyroid carcinoma. , 2009, Endocrine journal.